Patupilone (Epothilone B)

Catalog No.S1364 Synonyms: EPO906

For research use only.

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

Patupilone (Epothilone B) Chemical Structure

CAS No. 152044-54-7

Selleck's Patupilone (Epothilone B) has been cited by 15 publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Other Microtubule Associated Products

Biological Activity

Description Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.
Targets
Tubulin [1]
(Cell-free assay)
1.8 μM(EC0.01)
In vitro

Epothilone B shows better activity than Epothilone A. The EC0.01 of Epothilone B is 1.8 μM. Epothilone B potently inhibits cell proliferation in HCT116 cells, with IC50 of 0.8 nM. [1] Epothilone B induces mitotic arrest and displays cytotoxicity in KB3-1, KBV-1, Hela, and Hs578T cells, with IC50 of 3 nM to 92 nM. Epothilone B competes with Taxol in binding to microtubules, with IC50 of 3.3 μM. [2] In MCF-7 cells overexpressing GFP-α-tubulin, Epothilone B (3.5 nM) efficiently blocks microtubule dynamics. Meanwhile, Epothilone B induces mitotic arrest with IC50 of 3.5 nM. [3] In multiple myeloma (MM) cells, including RPMI 8226, U266, MM.1S, LR5, and MR20, Epothilone B directly suppresses proliferation with IC50 of 1 nM to 10 nM. Similarly, Epothilone B (10 nM) also induces cell cycle arrest and apoptosis. [4] A recent study reveals that, in ovarian cancer Hey cells, Epothilone B (5 nM–100 nM) enhances surface epithelial cell adhesion antigen (EpCAM), without affecting the transcription or the total cellular level of EpCAM. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LC-2-ad cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFnNPW5KdmirYnn0bY9vKG:oIHj1cYFvKEyFLUKtZYQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd5ZT2wOkDPxE1? NUG1NlBYW0GQR1XS
human A431 cell NYHpSVlCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2nnXGlvcGmkaYTpc44hd2ZiaIXtZY4hSTR|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuPFZmNTB4IN88US=> NYjtSJhIW0GQR1XS
human SW1710 cell NEPnW2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVLCNIhlUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjF2ZT2wOUDPxE1? NVfDeoI5W0GQR1XS
human Daoy cell Mn\ZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYGzW294UW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZnwxIxiSVO1NF0zNjd|ZT2wOUDPxE1? MVLTRW5ITVJ?
human BFTC-905 cell MmDrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGDHdI9KdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57OXWtNFUh|ryP MVXTRW5ITVJ?
human A375 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnzlTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NXWtNFUh|ryP NG\OWIFUSU6JRWK=
human RKO cell NVnm[og2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWHJcohq[mm2aX;uJI9nKGi3bXHuJHJMVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwNEflMVA2KM7:TR?= NG\MPYFUSU6JRWK=
human KYSE-510 cell MonFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYfWbmQ{UW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVUyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwM{jlMVA2KM7:TR?= M37ZSnNCVkeHUh?=
human HLE cell NHrRZpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEL2bmpKdmirYnn0bY9vKG:oIHj1cYFvKEiORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNlZmNTB3IN88US=> NF3uTIVUSU6JRWK=
human MCF7 cell NXfRfFVRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUnJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16Lk[2[U0xPSEQvF2= MkPTV2FPT0WU
human 786-0 cell M1TndGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mm[2TY5pcWKrdHnvckBw\iCqdX3hckA4QDZvMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVEhdk1? MkHoV2FPT0WU
human TE-8 cell NYTIXINXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NE\vbGZKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOSCwTR?= MmXHV2FPT0WU
ovarian carcinoma 1A9 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYDJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCxdnHybYFvKGOjcnPpco9u[SBzQUmgZ4VtdCCpcn;3eIg> NX\2S2RlOTZzM{S5Nlg>
human PANC-03-27 cell M{TtdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIHnVIpKdmirYnn0bY9vKG:oIHj1cYFvKFCDTlOtNFMuOjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGzNkDPxE1? NHXzXo9USU6JRWK=
human VMRC-RCZ cell M4jvVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3r6OmlvcGmkaYTpc44hd2ZiaIXtZY4hXk2UQz3SR3oh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|NjFOwG0> MnfOV2FPT0WU
human IGROV-1 cell M3;2c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGnHSI1KdmirYnn0bY9vKG:oIHj1cYFvKEmJUl;WMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3NjFOwG0> NVPWWFR3W0GQR1XS
human MG-63 cell M1f6Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX63UHNuUW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTZ3IN88US=> MonRV2FPT0WU
human SIG-M5 cell NYjuZ2dLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYfJcohq[mm2aX;uJI9nKGi3bXHuJHNKTy2PNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVY6KM7:TR?= M{joVHNCVkeHUh?=
human NCI-H650 cell NXviPVNCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWW0SG5MUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUeg{txO NYHiWopwW0GQR1XS
human PSN1 cell NHHDXpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1vZOWlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVc{KM7:TR?= MUTTRW5ITVJ?
human PA-1 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MonvTY5pcWKrdHnvckBw\iCqdX3hckBRSS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xO|Qh|ryP NFTPTZVUSU6JRWK=
KB-8511 cells NVvrS4UzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{X1[|czKGh? NU\4fFlYS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JJRp\SCpcn;3eIghd2ZicHHjcIl1[XinbD3y[ZNqe3SjboSgbJVu[W5iZYDp[IVzdW:rZDDjZZJkcW6xbXGgZ4VtdHNiS1KtPFUyOSCkeTC1NEBx\XKlZX70JEg4OiCqcjDlfJBwe3W{ZTmsJGlEPTB;MD6xPEDPxE1? MoTNNVEyOzNyOE[=
KB-31 cells NVGwXldoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoLTO|IhcA>? MnftR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IITo[UBoem:5dHigc4YheGGlbHn0ZZhmdC2|ZX7zbZRqfmViaIXtZY4h\XCrZHXycY9q\CClYYLjbY5wdWFiY3XscJMhU0JvM{GgZpkhPTBicHXyZ4VvfCBqN{KgbJIh\Xiyb4P1doUq NHr4UZIyOTF|M{C4Oi=>
human BHY cell MmLVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3fvdGlvcGmkaYTpc44hd2ZiaIXtZY4hSki\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xPVUhdk1? M4\WSnNCVkeHUh?=
human BB30-HNC cell Mm\KS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3G0R2lvcGmkaYTpc44hd2ZiaIXtZY4hSkJ|MD3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJyMTFOwG0> MmfqV2FPT0WU
human HOS cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3q3ZWlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNVUh|ryP MVnTRW5ITVJ?
human 639-V cell M2H5NGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXewVmk5UW6qaXLpeIlwdiCxZjDoeY1idiB4M{mtWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjF6IN88US=> M{\tOHNCVkeHUh?=
human ES1 cell  M1;RTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2[2e2lvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNlEh|ryP MU\TRW5ITVJ?
human TE-15 cell  MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmHITY5pcWKrdHnvckBw\iCqdX3hckBVTS1zNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlI2KM7:TR?= MVXTRW5ITVJ?
human LXF-289 cell MlzFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnsOnNKdmirYnn0bY9vKG:oIHj1cYFvKEy[Rj2yPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ5NzFOwG0> M3\pOnNCVkeHUh?=
human CAL-12T cell M3;OdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NILqSZRKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2xNnQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|OTFOwG0> M3GxR3NCVkeHUh?=
human T84 cell NIrQe2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWHJcohq[mm2aX;uJI9nKGi3bXHuJHQ5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkSg{txO NXTaS5FuW0GQR1XS
human KYSE-450 cell MonuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF70XoVKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOFUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{Nkeg{txO NXnISFROW0GQR1XS
human LCLC-103H cell NYK1[5hDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHe5TlZKdmirYnn0bY9vKG:oIHj1cYFvKEyFTFOtNVA{UCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{Ggcm0> NVeyU445W0GQR1XS
human NCI-H810 cell Mmm2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4DKSmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi4NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN{MjFOwG0> NVfaWoZbW0GQR1XS
human HUTU-80 cell NHTJPWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mo[zTY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OjhizszN MUTTRW5ITVJ?
human NCI-H460 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mm[2TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSES2NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN|IN88US=> MmDCV2FPT0WU
human HGC-27 cell NUH2cIJFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIf4PIhKdmirYnn0bY9vKG:oIHj1cYFvKEiJQz2yO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN6IN88US=> MYTTRW5ITVJ?
human HSC-2 cell NXuzWIFuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVPYUZlKUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzZ|IH7N NV;XdZRtW0GQR1XS
human IA-LM cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGTGWopKdmirYnn0bY9vKG:oIHj1cYFvKEmDLVzNJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTNizszN NUPISmREW0GQR1XS
human HMV-II cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4P2VGlvcGmkaYTpc44hd2ZiaIXtZY4hUE2YLVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTRizszN MoTyV2FPT0WU
human COLO-679 cell M4jLNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFnRdYZKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tOlc6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|OUSg{txO M{nBPHNCVkeHUh?=
human NCI-H2122 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmLJTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKxNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzIN88US=> M1;HNnNCVkeHUh?=
human CAL-39 cell MoDkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH[1TYZKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDFzIN88US=> NE\DU3lUSU6JRWK=
human SW954 cell MkPaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWDJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTV2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60N|Yh|ryP NHLoXpNUSU6JRWK=
human LCLC-97TM1 cell M3HOXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvOUfUUVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR2NDFOwG0> Mlu4V2FPT0WU
human KYSE-270 cell MkjYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MorVTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUK3NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDR3IN88US=> M1GzenNCVkeHUh?=
human NB13 cell M{XJXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYnYRYt4UW6qaXLpeIlwdiCxZjDoeY1idiCQQkGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PDdizszN Ml;0V2FPT0WU
human SK-LMS-1 cell MoLyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmHTTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OTWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjR4IN88US=> NWHKOXVWW0GQR1XS
human SW620 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV3GTpZFUW6qaXLpeIlwdiCxZjDoeY1idiCVV{[yNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjR6IN88US=> NHnwfYFUSU6JRWK=
human HCT-15 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NG\kZohKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzF5IN88US=> NWXQdoE1W0GQR1XS
human DU-145 cell MmPLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|IyKM7:TR?= NGCycZNUSU6JRWK=
human ST486 cell NGTRZodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWrJcohq[mm2aX;uJI9nKGi3bXHuJHNVPDh4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63NlEh|ryP NG[5foJUSU6JRWK=
human A427 cell NVfufGF7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGK0e4xKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlgzQCEQvF2= NUTv[YljW0GQR1XS
human HT-1080 cell NGLCdmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg1OiEQvF2= NFjoS4RUSU6JRWK=
human NCI-H2009 cell MoW0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHL3PHZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlAxQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOE[yJO69VQ>? M4TzbHNCVkeHUh?=
human SK-LU-1 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX7Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyXLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg3PiEQvF2= M3HJVHNCVkeHUh?=
human SCC-4 cell NI[3TmVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHNESy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64O|ch|ryP NV3kVHNtW0GQR1XS
human NCI-H1299 cell NGflWGNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2jEfmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNlk6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56ODFOwG0> NF3i[5BUSU6JRWK=
human NH-12 cell NXXveHNDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXHIUXJFUW6qaXLpeIlwdiCxZjDoeY1idiCQSD2xNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDlzIN88US=> NV\GXHJ3W0GQR1XS
human SK-UT-1 cell M{H6Zmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUW3VoF4UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OUKg{txO MVjTRW5ITVJ?
human Bel7402 NXroRZA{WHKxbHnm[ZJifGmxbjDhd5NigQ>? MoPoO|IhcA>? NGKzOVlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLlcFc1ODJiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmeiCJbH:gZZN{[XluIFnDOVA:OC57IN88US=> NFjaTnIzOjN{MEO1OC=>
human A388 cell NF2w[JhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFHRc|NKdmirYnn0bY9vKG:oIHj1cYFvKEF|OEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk1KM7:TR?= NHm5dVlUSU6JRWK=
human SW982 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3G0NWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk6QSEQvF2= NV3OT20xW0GQR1XS
In vivo In a mouse xenograft model of RPMI 8226 cells, Epothilone B (2.5 mg/kg–4 mg/kg) prolongs survival and suppresses tumor growth. [4] Similarly, in mouse xenograft models of prostate cancer cells, including DU145 and PC3, Epothilone B at the same dose also inhibits tumor growth. [6]

Protocol (from reference)

Kinase Assay:[1]
  • Tubulin polymerization assay:

    Calf brain microtubule proteins (MTP) are purified, which includes approximately 15%–20% microtubule associated proteins. The buffer (MES buffer) used for the Epothilone B-microtubule studies contains 0.1 M 2-morpholinoethanesulfonic acid (MES), 1 mM EGTA, 0.5 mM MgCl2, and 3 M glycerol at pH 6.6. Samples for electron microscopy are placed on carbon-over-Parlodion-coated grids (300 mesh) and negatively stained with 2% uranyl acetate. Microtubule assembly in the presence or absence of Epothilone B is monitored spectrophotometrically by using a spectrophotometer equipped with a thermostatically regulated liquid circulator. The temperature is held at 35 °C and changes in turbidity (representative of polymer mass) are monitored at 350 nm. Effective concentration (EC0.01), defined as the interpolated concentration capable of inducing an initial slope of 0.01 OD/min rate, is calculated using the formula EC0.01 = concentration/slope and expressed as the mean with standard deviation obtained from three different concentrations.

Cell Research:[2]
  • Cell lines: KB3-1, KBV-1, Hela, and Hs578T cells
  • Concentrations: 0–1 μM
  • Incubation Time: 72 hours
  • Method: For mitotic block and aberrant mitosis, cells are plated either in 48-well plates (for trypan blue and cell counting) or onto coverslips. After 24 hours, cells are treated with Epothilone B and scored at regular intervals. For the cytotoxicity analysis, cells are counted and scored as trypan blue positive or negative. Concurrently, coverslips andaliquots of cells in the culture supernatant are fixed and stained with Hoechst33342 in PBS. These cells are scored for cells blocked at the G2/M transition and aberrant mitosis.
Animal Research:[4]
  • Animal Models: Mice xenograft model of RPMI 8226 cells
  • Dosages: 2.5 mg/kg–4 mg/kg
  • Administration: Inject intravenously

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.

5 mg/mL

Chemical Information

Molecular Weight 507.68
Formula

C27H41NO6S

CAS No. 152044-54-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1CCCC2(C(O2)CC(OC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00496600 Completed Drug: Patupilone|Drug: RAD001 Refractory Malignancy University of Medicine and Dentistry of New Jersey|Novartis Pharmaceuticals|National Cancer Institute (NCI)|Rutgers The State University of New Jersey July 2007 Phase 1
NCT00442741 Withdrawn Drug: Patupilone|Drug: Patupilone + Omeprazole Solid Tumors Novartis Pharmaceuticals|Novartis July 2007 Phase 1
NCT00468260 Terminated Drug: Patupilone Advanced Malignancies Novartis Pharmaceuticals|Novartis May 2007 Phase 1
NCT00448396 Completed Drug: Patupilone Advanced Malignancies Novartis Pharmaceuticals|Novartis March 2007 Phase 1
NCT00426140 Completed Drug: Patupilone Advanced Malignancies|Solid Tumors Novartis Pharmaceuticals|Novartis August 2006 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Patupilone (Epothilone B) | Patupilone (Epothilone B) supplier | purchase Patupilone (Epothilone B) | Patupilone (Epothilone B) cost | Patupilone (Epothilone B) manufacturer | order Patupilone (Epothilone B) | Patupilone (Epothilone B) distributor